thalidomide has been researched along with Sleep Wake Disorders in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Sleep Wake Disorders: Abnormal sleep-wake schedule or pattern associated with the CIRCADIAN RHYTHM which affect the length, timing, and/or rigidity of the sleep-wake cycle relative to the day-night cycle.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To observe the effective mechanism and side effects of thalidomide to multiple myeloma (MM)." | 7.71 | [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism]. ( Li, Y; Liu, Y; Wang, M; Wu, H, 2002) |
| "Thalidomide was well tolerated: the most common side effects were constipation (76." | 6.71 | Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. ( Carillio, G; Fanelli, M; Gasparini, G; Gattuso, D; Morabito, A; Sarmiento, R, 2004) |
| "To observe the effective mechanism and side effects of thalidomide to multiple myeloma (MM)." | 3.71 | [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism]. ( Li, Y; Liu, Y; Wang, M; Wu, H, 2002) |
| "Thalidomide was well tolerated: the most common side effects were constipation (76." | 2.71 | Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. ( Carillio, G; Fanelli, M; Gasparini, G; Gattuso, D; Morabito, A; Sarmiento, R, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schmutz, JL | 1 |
| Wang, M | 1 |
| Liu, Y | 1 |
| Li, Y | 1 |
| Wu, H | 1 |
| Morabito, A | 1 |
| Fanelli, M | 1 |
| Carillio, G | 1 |
| Gattuso, D | 1 |
| Sarmiento, R | 1 |
| Gasparini, G | 1 |
1 trial available for thalidomide and Sleep Wake Disorders
| Article | Year |
|---|---|
Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Constipation; Disease Progression; Female; Glioblastoma; Heada | 2004 |
2 other studies available for thalidomide and Sleep Wake Disorders
| Article | Year |
|---|---|
[Apremilast withdrawals more frequent in standard practice than in clinical trials].
Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Depression; Female; Humans; Male; | 2018 |
[Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism].
Topics: Aged; Angiogenesis Inhibitors; Antigens, CD34; Bone Marrow; Constipation; Endothelial Growth Factors | 2002 |